Levels of p27kip1 determine Aplidin sensitivity

@article{Moneo2007LevelsOP,
  title={Levels of p27kip1 determine Aplidin sensitivity},
  author={V. Moneo and Beatriz G. Serelde and J. Leal and C. Blanco-Aparicio and R. D{\'i}az-Uriarte and M. Aracil and J. Tercero and J. Jimeno and A. Carnero},
  journal={Molecular Cancer Therapeutics},
  year={2007},
  volume={6},
  pages={1310 - 1316}
}
Aplidin (plitidepsin) is a novel anticancer drug isolated from the marine tunicate Aplidium albicans. Aplidin shows potent antitumor activity in preclinical models against a wide variety of human tumors. Aplidin is currently in phase II clinical trials in a variety of solid tumors and hematologic malignancies. Moreover, clinical studies of Aplidin in combination with other agents are ongoing because it generally lacks cross-resistance with other known cytotoxic drugs. The mode of action of… Expand
c-Jun N-Terminal Kinase Phosphorylation Is a Biomarker of Plitidepsin Activity
Aplidin as a potential adjunct to radiation therapy: In vitro studies
Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis
Levels of p27 Sensitize to Dual PI3K/mTOR Inhibition
Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1)
...
1
2
3
4
...

References

SHOWING 1-10 OF 46 REFERENCES
Antiangiogenic activity of aplidine, a new agent of marine origin
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine
VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia.
Extreme sensitivity to Yondelis® (Trabectedin, ET‐743) in low passaged sarcoma cell lines correlates with mutated p53
Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95- and mitochondrial-mediated mechanism.
Antitumor compounds from tunicates
...
1
2
3
4
5
...